Status:
WITHDRAWN
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Lead Sponsor:
Abbott
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
Eligibility Criteria
Inclusion
- Subject must have a histologically or cytologically confirmed non-hematologic malignancy.
- Subject must have an ECOG Score of 0-2.
- Adequate organ function.
Exclusion
- Subject has received targeted VEGF/PDGF therapy (tyrosine kinase inhibitor) therapy. Prior Avastin allowed.
- Subject has untreated brain or meningeal metastases.
- History of greater than 10% weight loss.
- Has clinically relevant hemoptysis.
- Subject has proteinuria CTC grade \> 1.
- Must not have had radiation therapy or major surgery within 21 days of study day 1.
- The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (DBP) \> 100 mmHg or systolic blood pressure (SBP) \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention.
- The subject has a documented left ventricular ejection fraction (LVEF) \< 50%.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00754104
Start Date
September 1 2008
Last Update
January 19 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.